News

As per the deal that has been approved unanimously by the boards of the two companies, Novartis will pay $218 for each share of AveXis. The deal will

The external data monitoring committee (eDMC) concluded that the pivotal phase 3 Echo-301/Keynote-205 study has failed to achieve the primary endpoint of improving progression-free survival in the overall

These lawsuits allege that the aforementioned companies infringe the '305 patent, which was issued on April 3rd and has been submitted for listing in the FDA's Orange Book.

Rebiotix has designed microbiota restoration therapy (MRT) drug platform, which aims to deliver healthy, live and human-derived microbes into a sick patient’s intestinal tract to treat disease. The

Proceeds from the financing will be used to advance Eidos' small molecule product candidate, AG10, into Phase 2 clinical trials and to continue preparations for Phase 3 clinical

The Company's proprietary triple combination includes a novel cystic fibrosis transmembrane conductance regulator (CFTR) amplifier, third generation corrector and potentiator, known as PTI-428, PTI-801 and PTI-808, respectively. The

The acquisition is the culmination of a June 2014 alliance between Inception and Roche to discover and develop novel small molecules that promote remyelination of nerve fibers damaged

The company has revealed the top-line results from the phase 3 study of Cyramza as a single agent in the second-line treatment of people with hepatocellular carcinoma (HCC).

Under the deal, the companies will jointly develop OSE-172, which is a SIRP-alpha antagonist targeting myeloid lineage cells. SIRP-alpha is a receptor showed by myeloid lineage cells such